Reuters
23 Jul 2026, 10:47 UTC · 1h ago
Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
23 Jul 2026, 10:47 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Eli Lilly's experimental obesity drug retatrutide showed positive results in two additional Phase 3 trials. — Positive late-stage trial data for a high-demand obesity drug significantly increases the probability of commercial success and future revenue growth.
+0.80Eli Lilly plans to submit an FDA application for retatrutide in the first quarter of next year. — Providing a concrete regulatory timeline creates a catalyst for investor valuation and marks the final step toward market entry.
+0.60Which stocks this story touches
Positive Phase 3 trial results for retatrutide and plans for FDA submission are significant positive developments.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
CNBC
1h ago
